Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Colorcon
Boehringer Ingelheim
Baxter
Moodys

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,290,504


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,290,504 protect, and when does it expire?

Patent 9,290,504 protects CALQUENCE and is included in one NDA.

This patent has fifty-five patent family members in thirty-six countries.

Summary for Patent: 9,290,504
Title:4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
Abstract: The present invention relates to 6-5 membered fused pyridine ring compounds according to formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to formula I in the treatment of Brutons Tyrosine Kinase (Btk) mediated disorders. ##STR00001##
Inventor(s): Barf; Tjeerd A. (Ravenstein, NL), Jans; Christiaan Gerardus Johannes Maria (Cuijk, NL), Man; Petrus Antonius De Adrianus (Hurwenen, NL), Oubrie; Arthur A. (Wijchen, NL), Raaijmakers; Hans C. A. (Eindhoven, NL), Rewinkel; Johannes Bernardus Maria (Berghem, NL), Sterrenburg; Jan-Gerard (Renkum, NL), Wijkmans; Jacobus C. H. M. (Oss, NL)
Assignee: Merck Sharp & Dohme B.V. (Haarlem, NL)
Application Number:14/233,418
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 9,290,504

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca CALQUENCE acalabrutinib CAPSULE;ORAL 210259-001 Oct 31, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,290,504

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
11174578Jul 19, 2011
PCT Information
PCT FiledJuly 11, 2012PCT Application Number:PCT/EP2012/063552
PCT Publication Date:January 24, 2013PCT Publication Number: WO2013/010868

International Family Members for US Patent 9,290,504

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2012285987   Start Trial
Australia 2016203837   Start Trial
Australia 2017279778   Start Trial
Australia 2019275591   Start Trial
Brazil 112014001255   Start Trial
Canada 2841886   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
AstraZeneca
Colorcon
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.